Search

Systemic lupus erythematosus is a systemic autoimmune disease associated with various manifestations. Here, we report a compelling case of a 42-year-old woman who presented with lupus enteritis as a sole manifestation of systemic lupus erythematosus and underwent 18F-FDG PET/CT. The resected bowel segment revealed vasculitis, and subsequent workup revealed positive antinuclear and anti–double-stranded antibody levels, confirming lupus enteritis, thus highlighting the diagnostic role of 18F-FDG PET/CT in reaching the final diagnosis.

Diffuse neurofibroma is a rare form of neurofibroma, usually reported in the head and neck. To our knowledge, diffuse neurofibroma of the anterior chest wall has not been reported previously. Even rarer is involvement of the sternum in neurofibroma. We report a case of a 30-year-old lady who presented with a rapidly growing, painless giant exophytic mass involving almost the entire anterior chest wall. The tumor mass was infiltrating the sternum. Excision of the tumor left a large full-thickness thoracic defect that was covered using polypropylene mesh beneath a pedicled omental flap with a split skin graft over it.

A projectile system is proposed to improve efficiency and effectiveness of damage done by anti-tank weapon system on its target by designing a ballistic projectile that can split into multiple warheads and engage a target at the same time. This idea has been developed in interest of saving time consumed from the process of reloading and additional number of rounds wasted on target during an attack. The proposed system is achieved in three steps: Firstly, a mathematical model is prepared using the basic equations of motion. Second, An Ejection Mechanism of proposed warhead is explained with the help of schematics. Third, a part of numerical simulation which is done using the MATLAB software. The final result shows various ranges and times when split can be effectively achieved. With the new system, impact points are increased and hence it has a better probability of hitting a target.

Nivolumab, a fully human immunoglobulin G4 anti–programmed cell death 1 antibody, provides a novel therapy option for patients with metastatic cancers. Immunotherapy agents have been associated with immune-related adverse events (irAEs), which may be detected on 18F-FDG PET/CT. Cutaneous toxicities are one of the most common irAEs in the form of maculopapular rash (eczema-like spongiotic dermatitis) and pruritus. These irAEs may lead to false-positive findings on PET/CT done during the treatment. One should be aware of the potential irAEs while interpreting PET/CT to avoid misinterpretation.